Účetní vykazování nákladů na vývoj vakcíny proti COVID-19 v IFRS a US GAAP

The thesis deals with the accounting treatment of costs incurred in the development of a vaccine against COVID-19 under the two most important accounting frameworks – International Financial Reporting Standards (IFRS) and US Generally Accepted Ac-counting Principles (US GAAP). The thesis is based on the fact that the COVID-19 pandemic has created extraordinary conditions for the development of new drugs, and the accounting treatment of the associated costs has had a significant impact on the financial statements of the pharmaceutical companies involved. The aim of the thesis is to describe the rules for the reporting of research and development costs under both systems, identify their main differences, and analyse specific approaches at selected companies. The theoretical part deals with the relevant provisions of IAS 38 and ASC 730 and their application in the context of drug development. The practical part analyses the financial statements of selected companies in order to assess their ap-proach to capitalizing development costs. The result of the thesis is an analysis and assessment of the impact of the COVID-19 pandemic on the reporting of drug devel-opment costs at selected companies involved in the production of COVID-19 vaccines.